Q-omics provides the consensus-scored ODF3B profile across patient tissues and cancer cell-line models. ODF3B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ODF3B is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, ODF3B RNA expression shows 16,061 significant gene co-expression associations, with the highest sampling consensus in READ. Together, these results highlight HNSC, KIRC, and READ as cancer lineages where ODF3B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ODF3B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ODF3B survival associations across molecular data types. ODF3B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ODF3B RNA expression–survival associations across cancer types. High ODF3B expression shows unfavorable associations in ACC, KIRC and LGG, but favorable associations in HNSC, SKCM and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for ODF3B RNA expression.
This table summarizes ODF3B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ODF3B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ODF3B shows lower tumor expression in LUAD and higher tumor expression in KIRC, KIRP, STAD, COAD and BLCA. The KIRC box plot shows higher ODF3B RNA expression in tumor versus normal tissue (log2 FC = +2.852, t-test p < 0.001).
This table shows molecular features associated with ODF3B in patient tissues and cancer cell lines. In patient samples, ODF3B shows the broadest associations at the RNA and protein expression levels, with READ recurring as the lineage with the largest associated feature set. In cancer cell lines, ODF3B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
